TEDIZOLID

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H15FN6O3
Molecular Weight	370.3378
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TEDIZOLID

Structure Search

SMILES

CN1N=NC(=N1)C2=NC=C(C=C2)C3=CC=C(C=C3F)N4C[C@H](CO)OC4=O

InChI

InChIKey=XFALPSLJIHVRKE-GFCCVEGCSA-N

InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C17H15FN6O3
Molecular Weight	370.3378
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:22:20 UTC 2023` Edited by `admin` on `Sat Dec 16 17:22:20 UTC 2023`
Record UNII	97HLQ82NGL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TEDIZOLID

Official Name

English

Tedizolid [WHO-DD]

Common Name

English

(5R)-3-{3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxymethyl)oxazolidin-2-one

Systematic Name

English

TOREZOLID

Common Name

English

tedizolid [INN]

Common Name

English

TEDIZOLID [USAN]

Common Name

English

TEDIZOLID [MI]

Common Name

English

TR-700

Code

English

2-OXAZOLIDINONE, 3-(3-FLUORO-4-(6-(2-METHYL-2H-TETRAZOL-5-YL)-3-PYRIDINYL)PHENYL)-5-(HYDROXYMETHYL)-, (5R)-

Systematic Name

English

TEDIZOLID [VANDF]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175495

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

WHO-ATC

J01XX11

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

NCI_THESAURUS

C258

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

Code System Code Type Description

RXCUI

1540825

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

RxNorm

USAN

UU-155

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

NDF-RT

N0000190113

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

Breast Cancer Resistance Protein Inhibitors [MoA]

PUBCHEM

11234049

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

CHEBI

82717

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

LACTMED

Tedizolid

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

MERCK INDEX

m10517

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

Merck Index

FDA UNII

97HLQ82NGL

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

WIKIPEDIA

Tedizolid

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

DAILYMED

97HLQ82NGL

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

SMS_ID

100000168846

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

ChEMBL

CHEMBL1257051

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

DRUG BANK

DB14569

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

CAS

856866-72-3

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

INN

9136

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

NCI_THESAURUS

C84222

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

EVMPD

SUB182420

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

EPA CompTox

DTXSID10234975

Created by admin on Sat Dec 16 17:22:21 UTC 2023 , Edited by admin on Sat Dec 16 17:22:21 UTC 2023

PRIMARY

Related Record Type Details


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					3OV8HVI592

AMINE OXIDASE (FLAVIN-CONTAINING) B

METABOLIC ENZYME -> INHIBITOR

Comments:

MAO inhibition can lead to peripheral or central neurotransmitter accumulation, with potentially serious consequences. MAO inhibitors, when taken in combination with vasoconstrictors, such as pseudoephedrine, or high dietary tyramine can cause sudden blood pressure elevations that may lead to hypertensive crises. Combination with serotonergic agents may lead to rare, but potentially life-threatening, serotonin syndrome

Qualification:

IC50

Amount:


					65P5WPF3BJ

METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

TARGET ORGANISM->INHIBITOR

Amount:


					TYR9KD6MVB

Tedizolid, (S)-

ENANTIOMER -> ENANTIOMER

Amount:

Related Record Type Details


					G5ADH118ED

CARBOXY TEDIZOLID

METABOLITE -> PARENT

Interaction Type:

MINOR

Qualification:

FECAL; URINE

Amount:


					2LN88S7R9P

TEDIZOLID O-SULFATE

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA; URINE

Amount:


					RXX49NX4AW

DESMETHYL TEDIZOLID SULFATE

METABOLITE -> PARENT

Amount:


					Z11QI50Q37

DESMETHYL TEDIZOLID

METABOLITE -> PARENT

Interaction Type:

MINOR

Qualification:

URINE

Amount:


					6MM3KJ999B

(3-FLUORO-4-(6-(2-METHYLTETRAZOL-5-YL)-3-PYRIDYL)PHENYL)-METHYL-CARBAMIC ACID

METABOLITE -> PARENT

Amount:


					O7DRJ6R4DW

TEDIZOLID PHOSPHATE

PRODRUG -> METABOLITE ACTIVE

Amount:

Related Record Type Details


					97HLQ82NGL

TEDIZOLID

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Tmax	PHARMACOKINETIC				SINGLE DOSE ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC

Tmax	PHARMACOKINETIC				SINGLE DOSE INTRAVENOUS ADMINISTRATION